Advertisement

We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

EMA

EU regulator brings Moderna vaccine decision forward to 6 January

The date for a decision had been 12 January.

LAST UPDATE | 17 Dec 2020

THE EU MEDICINE’S watchdog has said that it had brought forward the date for a decision on authorising Moderna’s coronavirus vaccine by nearly a week to 6 January.

The Amsterdam-based European Medicines Agency has been under growing pressure to speed up, and earlier this week accelerated the timeframe for Pfizer/BioNTech’s jab.

The EMA had originally been due to decide on US-based Moderna’s vaccine on 12 January, but said the company had submitted extra data today “ahead of schedule”.

“Taking due account of the progress made, the Committee has scheduled an extraordinary meeting on 6 January 2021 to conclude its assessment, if possible,” the EMA said, referring to the medicines committee that decides on such issues.

“The meeting planned for 12 January 2021 will be maintained if needed.”

A clinical trial of 30,400 people found the Moderna vaccine was 94.1% effective in preventing Covid-19 compared to a placebo, performing slightly better in younger adults compared to the elderly.

According to the Irish government’s National Covid-19 Vaccination Strategy, Ireland has ordered 880,000 doses of Moderna’s vaccine. 

EMA chief Emer Cooke said today the under-fire agency had shown it was able to respond.

“We have been able to revise the timetables for the evaluation of the Covid-19 vaccines due to the incredible efforts of everybody involved in these assessments,” Cooke said in a statement.

“The number of infections is increasing across Europe and we are aware of the huge responsibility we have to get a vaccine to the market as quickly as is feasible, whilst maintaining the robustness of our scientific review.”

With Britain and the United States having pushed through emergency authorisation of the Pfizer/BioNTech vaccine, the EMA has been under pressure to speed up, notably from Germany.

The watchdog, which moved from London last year after Brexit, will decide on a year-long “conditional marketing authorisation” for Pfizer/BioNTech on Monday, having brought the date forward from 29 December.

© AFP 2020

Your Voice
Readers Comments
16
This is YOUR comments community. Stay civil, stay constructive, stay on topic. Please familiarise yourself with our comments policy here before taking part.
Leave a Comment
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.

    Leave a commentcancel